Back to Authors

Colletti, Patrick M.

https://orcid.org/0000-0001-9625-8046

Mayo Clinic

Boston Medical Center

Citations 2

ACR–ACNM Practice Parameter for the Performance of Dopamine Transporter (DaT) Single Photon Emission Computed Tomography (SPECT) Imaging for Movement Disorders
Subramaniam, Rathan M. , Frey, Kirk A. , Sólnes, Lilja B. , Colletti, Patrick M. , Lü, Yang , Savir-Baruch, Bital , Williams, Hadyn T. , Hunt, Christopher H. , Mercier, Gustavo

Clinical Nuclear Medicine | September 15, 2017 | Volume: 42 | Issue: 11 | Pages: 847-852

10.1097/rlu.0000000000001815 Get It

Abstract This American College of Radiology and American College of Nuclear Medicine joint clinical practice parameter is for performance of dopamine transporter single photon emission computed tomography (SPECT) imaging, for patients with movement disorders. Parkinsonian syndrome (PS) consists of a group of neurodegenerative diseases including Parkinson disease (PD), progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal degeneration (CBD), and dementia with Lewy bodies (DLB). Accurate diagnosis of PS is critical for clinical management. An important diagnostic dilemma is the differentiation of PS and non-neurodegenerative disorders, such as essential tremor (ET) or drug-induced tremor, due to the overlap of clinical symptoms. The management approach to these conditions is distinctly different. An abnormal iodine-123 ioflupane SPECT scan suggests a decreased amount of dopamine transporter in the striatum, that is, a diagnosis of nigrostriatal neurodegenerative PS, whereas a normal scan suggests ET or other nondegenerative parkinsonism (drug-induced, vascular, or psychogenic).
Panel Discussion: Pulmonary Embolism Imaging and Outcomes
Araoz, Philip A. , Haramati, Linda B. , Mayo, John R. , Barbosa, Eduardo Jose Mortani , Rybicki, Frank J. , Colletti, Patrick M. , Haramati, Linda B

American Journal of Roentgenology | May 22, 2012 | Volume: 198 | Issue: 6 | Pages: 1313-1319

10.2214/ajr.11.8461 Get It